Menu
Search Close

Company

Partnering Opportunities

To discuss partnering opportunities, please contact Richard Goodfellow richardgoodfellow@scancell.co.uk

Current Collaborations 

Our partners are listed below. To visit their sites simply click on the web address.

CRUK

 

BioNTech

 

Cancer Research Technology Limited


NIH

  • Worldwide licence for use of TRP-2 and gp100
  • www.nih.gov


Ichor Medical Systems

 

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00